SMYD3 and prostate cancer: Similarly, SET and MYND domain-containing protein 3 (SMYD3) has also been identified as an upregulated H3 and H4 lysine methyltransferase promoting cell proliferation and migration, thus emerging as a predictive marker of prostate cancer [10].